Soft tissue sarcomas are rare malignant tumors of mesenchymal origin, accounting for approximately 1 % of adult cancers. Their diagnostic and therapeutic complexity requires multidisciplinary management at specialized reference centers. Diagnosis relies on imaging, primarily MRI, as well as on anatomopathological and molecular analysis of a planned biopsy. Surgery with negative margins (R0) remains the standard treatment, often combined with neoadjuvant radiotherapy or chemotherapy, depending on the lesion's type, grade, and resectability. Systematic discussion within a multidisciplinary sarcoma tumor board optimizes the therapeutic strategy, reduces diagnostic errors, and improves both overall and functional patient outcomes.